Pre-Eclampsia Clinical Trial
Official title:
Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women in Abakaliki
Background: Preeclampsia is one of the leading causes of maternal and perinatal morbidity and
mortality worldwide, and it affects 3% to 8% of all pregnancies. Maternal and perinatal
morbidity and mortality resulting from preeclampsia are due to its complications. Clinical
prediction of complications associated with preeclampsia may facilitate initiation of timely
management to reduce or avert adverse outcomes associated with the condition. Studies on
current biomarkers (proteinuria or uric acid) have shown poor performance in the prediction
of adverse pregnancy outcomes in preeclamptic women. Placental growth factor (PlGF) is an
angiogenic growth factor that is exclusively produced by the trophoblast. Circulating levels
of placental growth factor have been reported to be reduced in women with preeclampsia.
Therefore there is a need to evaluate the predictive performance on adverse pregnancy
outcomes of this pregnancy specific biomaker among preeclamptic women.
Aim: To determine the predictive accuracy of maternal serum PlGF level for adverse pregnancy
outcomes in preeclamptic women.
Materials and Method: It is a prospective cohort study that will be conducted on 110 women
that will be admitted for preeclampsia in the Federal Teaching Hospital and Saint Patrick
Mile 4 Hospital Abakaliki. On admission women who will give informed consent will have their
blood sample collected. The sample will be analysed using Enzyme linked Immunosorbent Assay
technique to determine the level of PlGF (pg/ml). All the study participants will be followed
up until delivery. The socio-demographic characteristics and maternal and perinatal adverse
outcomes will be entered into a proforma. Data will be entered and analyzed using SPSS
version 22.0.
Strength and limitation: The strength of the study is that a single biomaker, PlGF, will be
assayed and the test will be performed once, which is cost-saving. The limitation of this
study is that there would not be long term follow up of participants after hospital discharge
and so complications that will occur after discharge will not be assessed.
Conclusion: Considering the contribution of preeclampsia to maternal morbidity and mortality
in Abakaliki and poor predictive performance of available biochemical markers on adverse
pregnancy outcomes among preeclamptic women, there is need to conduct this study so as to
ascertain the utility of PlGF in predicting adverse outcome among preeclamptic women in
Abakaliki.
INTRODUCTION Despite advances in care, preeclampsia remains a leading cause of maternal and
perinatal morbidity and mortality worldwide and its syndromic nature makes diagnosis and
management difficult.1 Preeclampsia (PE) is a pregnancy-specific syndrome, defined by new
onset hypertension and proteinuria after 20 weeks of gestation.2 It complicates 2-8% of
pregnancies and accounts for more than 50,000 maternal death annually.2,3 In developing
countries, where lack of access to appropriate maternal care is a major problem, maternal
death rates are as high as 15% as compared with 0% to 1.8% in industrialized countries.1 A
10-year review of maternal mortality in Ebonyi state University Teaching Hospital showed that
PE and eclampsia accounted for 6.1% of maternal death.4 Preeclampsia affects multiple organ
systems and can lead to severe maternal and fetal complications.5-10 Maternal and perinatal
morbidity and mortality resulting from PE are due to its complications.6-8 Maternal
complications include eclampsia, cerebrovascular accident, placental abruption, disseminated
intravascular coagulation, hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome,
liver hemorrhage or rupture, pulmonary edema, adult respiratory distress syndrome, acute
renal failure, and death. Perinatal consequences include stillbirth, preterm delivery, fetal
growth restriction (FGR), and neonatal death.5-10 The only curative treatment for PE is
delivery of the placenta.9-13 The challenge in caring for women with PE is to identify those
who are at increased risk of complications so that appropriate and timely delivery can be
offered.14 Most of the symptoms associated with PE are common and nonspecific, which can lead
to poor predictability of adverse outcomes.15 Moreover, the capacity to predict adverse
maternal and perinatal outcomes remains poor.15 Recognition of those patients at risk of
adverse outcomes related to PE can reduce or avert maternal and perinatal morbidity and
mortality associated with the condition.16 Currently available biochemical makers such as
proteinuria and uric acid have been shown to be poor predictors of adverse pregnancy outcomes
in preeclamptic women.16-20 This suggests that a clinical diagnostic test able to predict
maternal and fetal risk could be useful. Among biochemical markers, attention has recently
focused on angiogenic factors, such as PlGF. Placental growth factor is an angiogenic growth
factor related to vascular endothelial growth factor that is exclusively produced by the
trophoblast.18 A growing body of evidence suggests that an imbalance of
angiogenic/anti-angiogenic factors are involved in the pathophysiology of PE.18 Studies on
the pathogenesis of PE support the hypothesis of a pathogenetic model of defective
placentation resulting from reduced concentrations of angiogenic growth factors (free PlGF)
and increased concentrations of anti-angiogenic factors such as soluble Fms-like tyrosine
kinase-1 (sFlt-1).16-24 The majority of studies of PlGF testing have focused on either
prediction of PE or confirmation of the diagnosis once PE is suspected. Even though this
biomarker has excellent predictive value for PE, a major issue is that there is no clear
intervention that can prevent the subsequent development of the disease. Several preventive
measures such as supplementation with vitamin C and vitamin E, aspirin, or calcium fail to
consistently prevent subsequent development of PE.19 Thus, the value remains either a
"research procedure" or a method of risk assessment to identify patients who may benefit from
more intensive surveillance. Currently studies are focused on evaluating the role of plasma
angiogenic and anti-angiogenic factors in predicting the outcome of patients with PE. Studies
have shown a positive correlation between low maternal serum PlGF levels and adverse maternal
and fetal outcomes.21 These findings have led to speculation that PlGF might be useful in
both the prediction of PE and prognosis with respect to the occurrence of related adverse
outcomes.
Considering the contribution of PE to maternal morbidity and mortality in Abakaliki and poor
predictive accuracy of available biochemical markers on adverse pregnancy outcomes and the
search for better predictive maker of adverse outcomes among preeclamptic women, a study on
PlGF as a predictor of outcomes among preeclamptic women in Abakaliki is important.
1.1 JUSTIFICATION FOR THE STUDY Preeclampsia has remained among the leading causes of
maternal morbidity and mortality worldwide.22 Maternal deaths resulting from PE are due to
complications associated with the condition.20-25 Clinical prediction of disease
complications may facilitate initiation of timely management to prevent morbidity and
mortality in the mother and baby. The studies on current predictive biomarkers (proteinuria
or uric acid) of adverse outcomes among preeclamptic women have shown poor predictive
results.24 Hence there is a need for identification of highly specific and sensitive
biomarkers that would allow early identification of patients at risk and for prediction of
adverse outcomes for women who developed the condition and thus help in providing proper
prenatal care. Placental growth factor appears to be a promising tool in this regard.
Literature search showed that this study has not been done in Abakaliki. Hence, the outcome
of this study will help to make evidence based recommendations on the role of maternal serum
level of PlGF in the management of preeclamptic women in Abakaliki.
3.0 AIM AND OBJECTIVES AND RESEARCH QUESTION 3.1 AIM The aim of the study is to test the
predictive accuracy of maternal free PlGF concentration for pregnancy adverse outcomes in
patients with preeclampsia based on a single assay at the time of admission.
3.2 SPECIFIC OBJECTIVES To compare the mean serum level of PlGF among preeclamptic women with
and without adverse pregnancy outcomes.
To evaluate the relationship between the level of PlGF and adverse maternal outcomes.
To determine the association between serum PlGF level and adverse perinatal outcomes.
To estimate the cut off value of PlGF associated with adverse pregnancy outcomes.
To determine the sensitivity and specificity of cut off value of PlGF associated with adverse
pregnancy outcomes.
3.3 RESEARCH QUESTION Is maternal PlGF level predictive of adverse pregnancy outcomes in
preeclamptic women in the Federal Teaching Hospital and Saint Patrick Mile 4 Hospital
Abakaliki? 3.4 NULL HYPOTHESIS There is no association between maternal serum PlGF
concentration and adverse pregnancy outcomes in preeclamptic women 3.5 ALTERNATE HYPOTHESIS
There is an association between maternal PlGF level and adverse pregnancy outcomes in
preeclamptic women.
4.0 METHODOLOGY 4.1 STUDY AREA This study will be done at the antenatal ward, labour ward,
postnatal ward and neonatal intensive care unit department of the Federal Teaching Hospital,
Abakaliki, Ebonyi State.
Federal Teaching Hospital, Abakaliki is a federal tertiary health care institution located at
the state capital. It is a product of a merger of the former Federal Medical Centre,
Abakaliki and the then Ebonyi State University Teaching Hospital by the Federal Government of
Nigeria in 2011. The department of Obstetrics and Gynaecology of the hospital maintains
gynaecological emergency, antenatal clinic, antenatal ward, labour ward, theatre complex and
postnatal ward for both booked and unbooked patients. These are managed by Consultants and
Resident Doctors with trained Nurses and Midwives. There are 25 Consultants manning 5 units
in the department with an average of 5 Consultants per unit. The units run the antenatal and
gynaecological clinics on each of the working days of the week. In 2017, three thousand and
two hundred deliveries were taken and there were 204 cases of preeclampsia. The maternal
mortality ratio in a 10 year review of maternal death in the hospital was 1, 359 per 100,000
live births.4 Ebonyi State is one of the five states in the Southeast geopolitical zone of
Nigeria created in 1996 from the old Abakaliki division of Enugu State and old Afikpo
division of former Abia State. It has 13 local government areas with an estimated population
of about 4.3 million, with a land mass of approximately 5, 932 sq km.33 The state is bordered
in the north by Benue State, east by the Cross river Sate; south by Abia State and West by
Enugu state.
4.2 SAMPLING METHOD Total sampling method will be used for the study. All women diagnosed
with preeclampsia on admission who meet the inclusion criteria and give informed consent will
be recruited for the study. The study participants will be followed up until hospital
discharge after delivery.
4.3 DIAGNOSIS OF PREECLAMPSIA Measurement of blood pressure: Upper arm blood pressure will be
measured by the researcher or research assistant using the Mercury Sphygmomanometer (ELKO B.P
APPARATUS) after the study participant has rested for 5 minutes. All of the participants will
be seated on a chair in an upright position with back support. A cuff will be placed around
the non-dominant upper arm, which will be supported at the level of the heart; with the
bladder of the cuff in the midline over the brachial artery pulsation. The systolic and
diastolic blood pressures will be determined by Korokoff I and V respectively.
Preeclampsia will be defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or
diastolic blood pressure ≥ 90 mmHg on ≥ 2 recordings taken ≥ 4 hours apart after 20 weeks'
gestation or a single measurement of systolic blood pressure of 160 mmHg and/or diastolic
blood pressure of 110 mmHg with proteinuria (≥ 2+ by dipstick).
4.4 SAMPLE SIZE ESTIMATION The sample size calculation was based on the formula N=Z^2 x
SD^2/d^2 Z1-α = Standard normal variate at 5% type 1 error (P<0.05) is 1.96 SD = Standard
deviation of variable based on previous studies (The SD of PlGF value which preeclamptic
women were predicted to developed adverse pregnancy outcomes was 0.56. Note: 0.56 was derived
by getting the average SD of PlGF for developing adverse pregnancy outcomes from two previous
studies ).25,26 d = Absolute error or precision (set at 10%) Therefore, N= 120.5 Adding 10%
attrition rate which is approximately 12. Therefore the sample size is 140.
4.5 SPECIMEN COLLECTION AND TRANSPORT On admission women who give consent for the study will
have their urine and blood samples taken. Bed side urinalysis to know the degree of
proteinuria will be carried out by the researcher or research assistants using True-Screen
Combi 11 reagent strips (Lifesane Biotech, USA). The blood sample will be taken and
transferred to a universal specimen bottle and the specimen taken to the hospital laboratory
for analysis.
4.6 SPECIMEN PROCESSING, STORAGE AND ANALYSIS At laboratory processing of the specimen will
be carried out by three medical laboratory scientists and the researcher. Assay will be
performed as soon as 40 samples are ready. Estimation of free PlGF levels will be done by
ELISA technique using the Human PlGF ELISA kit (Roche Diagnostics, Germany). The result of
the test will be reported in pg/ml.
4.7 QUALITY CONTROL Three medical laboratory scientists will be involved in the sample
analysis with the aid of the researcher under the supervision of a chemical pathologist.
Three laboratory scientists will be dedicated to sample analysis while the chemical
pathologist will occasionally test random samples to ensure that the results are
corresponding with results of the test samples from the other three.
4.8 RESEARCH ASSISTANTS Research assistants comprise the 2 residents and 5 house officers
from each team and each assigned a specific role to play during the study period. There will
be three training sessions for the assistants during which the details of the study with the
role of each assistant will be explained. Retraining sessions may be done in the course of
the study if deemed necessary. Whatsapp chat group will be created for easy communication.
4.9 DATA COLLECTION METHOD The data would be collected using a proforma that has four parts
which include the socio-demographic characteristics of the study participants, Blood
pressure, Urinalysis result, adverse maternal and perinatal outcomes and PlGF level. After
delivery, data proforma sheets will be completed for all participants before entering the
information into a database.
4.10 STATISTICAL ANALYSIS The data analysis will be performed using the SPSS version 22.0
program for Windows (IBM Corp. Amork, New York, U.S.A). Categorical variables would be
presented as frequencies and percentages while continuous variables would be presented as
mean ± standard deviation. The mean PlGF values of women with and without adverse outcomes
will be compared using the Student's t-test. To determine the best cut off value of PlGF
(designated as X) for the prediction of adverse outcomes, the receiver operating
characteristic (ROC) curve analysis would be used and areas under the curve (AUC) calculated.
Logistic regression would be used to determine the association between the cut off value of
PlGF and each of the composite maternal and perinatal adverse outcomes. Multivariable
logistic regression would be constructed to account for potentially confounding factors
selected based on clinical information (maternal age, gestational age at presentation, parity
and mode of delivery). The sensitivity and specificity would be determined for the cut point
cited above. A p value <0.05 would be considered statistically significant.
4.11.0 ETHICAL CONSIDERATION 4.11.1 ETHICAL APPROVAL Ethical approval for the study has been
sought for and obtained from the hospital Research Ethics Committee with approval number
FETHA/REC/VOL2/2018/041. Informed consent will be obtained from each study participants.
4.12 SOURCE OF FUNDING There is no source of funding for this study. The researchers will
bear the cost of the study.
4.13 STRENGTH AND LIMITATION OF THE STUDY The strength of the study is that a single
biomaker, PlGF, would be assayed and the test would be performed once, which is cost-saving.
The limitation of this study is that long term follow up of participants will not be carried
out and adverse outcomes that will occur following hospital discharge will not be assessed.
In addition, reliable results are obtained when the assay procedure is performed with a
complete adherence to good laboratory practice and this will be ensured by quality control
that will be put in place in course of the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03299777 -
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
|
N/A | |
Completed |
NCT03650790 -
C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies
|
N/A | |
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT03302260 -
Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT02911701 -
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
|
Phase 4 | |
Completed |
NCT01911494 -
Community Level Interventions for Pre-eclampsia
|
N/A | |
Terminated |
NCT02025426 -
Phenylephrine Versus Ephedrine in Pre-eclampsia
|
Phase 4 | |
Completed |
NCT01352234 -
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
|
Phase 4 | |
Active, not recruiting |
NCT02031393 -
Establishing First Trimester Markers for the Identification of High Risk Twin
|
N/A | |
Terminated |
NCT00141310 -
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
|
Phase 2 | |
Completed |
NCT00157521 -
L-Arginine in Pre-Eclampsia
|
Phase 3 | |
Completed |
NCT04795154 -
Prenatal Yoga as Complementary Therapy of Preeclampsia
|
N/A | |
Completed |
NCT00004399 -
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
|
N/A | |
Completed |
NCT00005207 -
Renin and Prorenin in Pregnancy
|
N/A | |
Recruiting |
NCT04551807 -
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
|
Phase 3 | |
Terminated |
NCT04092829 -
Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer
|
N/A | |
Recruiting |
NCT06067906 -
Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients
|
N/A | |
Recruiting |
NCT06317467 -
Role of Anti-C1q Autoantibodies in Pregnancy
|
||
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Active, not recruiting |
NCT04484766 -
Preeclampsia Associated Vascular Aging
|